|
AU609031B2
(en)
|
1986-03-12 |
1991-04-26 |
American Cyanamid Company |
Macrolide compounds
|
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
|
DE69129226T2
(de)
|
1990-01-24 |
1998-07-30 |
Douglas I. Woodside Calif. Buckley |
Glp-1-analoga verwendbar in der diabetesbehandlung
|
|
JPH08510205A
(ja)
|
1993-03-29 |
1996-10-29 |
ユニバーシティ オブ シンシナティ |
Ｙｙペプチドのアナログとその用途
|
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
|
WO1995033474A1
(fr)
|
1994-06-03 |
1995-12-14 |
Tsumura & Co. |
Composition medicinale
|
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
|
US5574010A
(en)
|
1994-11-14 |
1996-11-12 |
The Regents Of The University Of California |
Treatment of pancreatic tumors with peptide YY and analogs thereof
|
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
|
CN1151836C
(zh)
|
1995-03-31 |
2004-06-02 |
艾米斯菲尔技术有限公司 |
用作传送活性剂的化合物和组合物
|
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
DE69737479D1
(de)
|
1996-08-30 |
2007-04-26 |
Novo Nordisk As |
Glp-1 derivate
|
|
AU4863797A
(en)
|
1996-11-12 |
1998-06-03 |
Novo Nordisk A/S |
Use of glp-1 peptides
|
|
CA2271788A1
(en)
|
1996-11-13 |
1998-05-22 |
University Of Cincinnati |
Analogs of peptide yy and uses thereof
|
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
EP0908515A3
(en)
|
1997-09-16 |
2000-04-26 |
Smithkline Beecham Plc |
Pancreatic polypeptide
|
|
EP1062240B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
|
EP1060191B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Derivatives of glp-1 analogs
|
|
AU2610599A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
US6046167A
(en)
|
1998-03-25 |
2000-04-04 |
University Of Cincinnati |
Peptide YY analogs
|
|
KR20010052587A
(ko)
|
1998-06-08 |
2001-06-25 |
둘락 노먼 씨. |
뉴로펩티드 ｙ5 수용체 길항제
|
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
|
ATE251465T1
(de)
|
1998-07-31 |
2003-10-15 |
Novo Nordisk As |
In-vitro stimulation von beta zellen vermehrung
|
|
MY155270A
(en)
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
|
PL202367B1
(pl)
|
1998-12-07 |
2009-06-30 |
Sod Conseils Rech Applic |
Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków
|
|
EP1149066B1
(en)
|
1999-02-05 |
2005-11-09 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
|
EP1154761B1
(en)
|
1999-02-22 |
2008-02-20 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
|
AU3240900A
(en)
|
1999-02-22 |
2000-09-04 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
|
CN1372570A
(zh)
|
1999-04-30 |
2002-10-02 |
安米林药品公司 |
修饰的exendin和exendin激动剂
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
|
ES2209885T3
(es)
|
1999-05-17 |
2004-07-01 |
Conjuchem, Inc. |
Peptidos insulinotropicos de larga duracion.
|
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
GB9923436D0
(en)
|
1999-10-04 |
1999-12-08 |
American Home Prod |
Pharmaceutical compositions
|
|
US6793934B1
(en)
|
1999-12-08 |
2004-09-21 |
Shire Laboratories, Inc. |
Solid oral dosage form
|
|
US7262325B2
(en)
|
2000-06-02 |
2007-08-28 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
|
US7049283B2
(en)
|
2000-12-06 |
2006-05-23 |
Novartis Ag |
Pharmaceutical compositions for the oral delivery of pharmacologically active agents
|
|
PT1355942E
(pt)
|
2000-12-07 |
2008-11-21 |
Lilly Co Eli |
Proteínas de fusão de glp-1
|
|
US7199217B2
(en)
|
2000-12-13 |
2007-04-03 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
|
EP2186824A3
(en)
|
2000-12-13 |
2010-09-22 |
Eli Lilly & Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
RU2275207C2
(ru)
|
2000-12-14 |
2006-04-27 |
Амилин Фармасьютикалз, Инк. |
Способ снижения доступности питательного вещества, способ подавления аппетита
|
|
GB0102075D0
(en)
|
2001-01-26 |
2001-03-14 |
Astrazeneca Ab |
Process
|
|
US6589938B2
(en)
|
2001-06-29 |
2003-07-08 |
National University Of Singapore |
Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
|
|
US20030068356A1
(en)
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
|
CN100350968C
(zh)
|
2001-09-24 |
2007-11-28 |
皇家创新有限公司 |
饮食行为的改进
|
|
WO2003045331A2
(en)
|
2001-11-29 |
2003-06-05 |
Emisphere Technologies, Inc. |
Formulations for oral administration of cromolyn sodium
|
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
|
CA2474809A1
(en)
|
2002-02-01 |
2003-08-07 |
Pfizer Products Inc. |
Dry granulated formulations of azithromycin
|
|
PL209734B1
(pl)
|
2002-02-20 |
2011-10-31 |
Emisphere Tech Inc |
Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
|
|
DK1525219T3
(da)
|
2002-07-04 |
2009-09-07 |
Zealand Pharma As |
GLP-1 og fremgangsm der til behandling af diabetes
|
|
JP2004131398A
(ja)
|
2002-10-08 |
2004-04-30 |
Taihei Chemical Industrial Co Ltd |
錠剤用滑沢剤
|
|
EP1583549A4
(en)
|
2003-01-17 |
2006-10-04 |
Sod Conseils Rech Applic |
YY PEPTIDE ANALOGS
|
|
US20050059605A1
(en)
|
2003-01-31 |
2005-03-17 |
Krishna Peri |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
|
EA009366B1
(ru)
|
2003-03-19 |
2007-12-28 |
Эли Лилли Энд Компани |
Связанные с полиэтиленгликолем соединения гпп-1
|
|
US20050009748A1
(en)
|
2003-05-14 |
2005-01-13 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide YY and PYY agonists
|
|
US7572581B2
(en)
|
2003-06-30 |
2009-08-11 |
Roche Molecular Systems, Inc. |
2′-terminator nucleotide-related methods and systems
|
|
CA2529604C
(en)
|
2003-07-11 |
2012-05-08 |
Novartis Ag |
Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
|
|
WO2005014049A2
(en)
|
2003-08-08 |
2005-02-17 |
Novo Nordisk A/S |
Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
|
|
CN101380476A
(zh)
|
2003-09-19 |
2009-03-11 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
|
TW200526254A
(en)
|
2003-09-19 |
2005-08-16 |
Novo Nordisk As |
Novel GLP-1 derivatives
|
|
DK1687019T3
(en)
|
2003-11-20 |
2018-02-12 |
Novo Nordisk As |
Propylene glycol peptide formulations that are optimal for production and use in injection devices
|
|
MXPA06006746A
(es)
|
2003-12-18 |
2006-08-18 |
Novo Nordisk As |
Analogos de glp-1 novedosos ligados a agentes similares a albumina.
|
|
KR20060135661A
(ko)
|
2003-12-18 |
2006-12-29 |
노보 노르디스크 에이/에스 |
신규 ｇｌｐ-1 화합물
|
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
EP2335716A3
(en)
|
2004-02-11 |
2011-10-19 |
Amylin Pharmaceuticals Inc. |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
EP1718665B1
(en)
|
2004-02-11 |
2013-04-10 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
|
US20080269114A1
(en)
|
2004-03-17 |
2008-10-30 |
7Tm Pharma A/S |
Y4 Selective Receptor Agonists For Thereapeutic Interventions
|
|
EP1786458A2
(en)
|
2004-03-17 |
2007-05-23 |
7TM Pharma A/S |
Y2/y4 selective receptor agonists for therapeutic interventions
|
|
CN100425282C
(zh)
|
2004-03-17 |
2008-10-15 |
7Tm制药联合股份有限公司 |
用于治疗性干预的y2/y4选择性受体激动剂
|
|
JP2007531713A
(ja)
|
2004-03-17 |
2007-11-08 |
７ティーエム ファーマ エイ／エス |
治療的介入のためのｙ２選択性レセプターアゴニスト
|
|
WO2005099672A1
(en)
|
2004-04-13 |
2005-10-27 |
Ranbaxy Laboratories Limited |
A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
|
|
MXPA06012842A
(es)
|
2004-05-06 |
2007-02-15 |
Emisphere Tech Inc |
Formas poliformicas cristalinas de monosodio n-[8-(2-hidroxibenzoil)amino]caprilato.
|
|
KR20070008720A
(ko)
|
2004-05-06 |
2007-01-17 |
에미스페어 테크놀로지스, 인코포레이티드 |
습윤 헤파린의 고체 투여형
|
|
MXPA06013252A
(es)
|
2004-05-14 |
2007-02-28 |
Emisphere Tech Inc |
Compuestos y composiciones para suministrar agentes activos.
|
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
|
WO2005121090A1
(en)
|
2004-06-02 |
2005-12-22 |
Abbott Laboratories |
Substituted piperidines that have antiangiogenic activity
|
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
|
US20070021346A1
(en)
|
2005-05-26 |
2007-01-25 |
Ewing William R |
N-terminally modified GLP-1 receptor modulators
|
|
CN101010339B
(zh)
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
|
EP2289560B1
(en)
|
2004-07-08 |
2015-04-22 |
Novo Nordisk A/S |
Polypeptide protracting tags comprising a tetrazole moiety
|
|
WO2006017251A2
(en)
|
2004-07-12 |
2006-02-16 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide yy and pyy agonists
|
|
US7994119B2
(en)
|
2004-07-19 |
2011-08-09 |
University Of Cincinnati |
Compounds for control of appetite
|
|
US20060078623A1
(en)
|
2004-08-13 |
2006-04-13 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
|
WO2006049681A2
(en)
|
2004-08-30 |
2006-05-11 |
Bayer Pharmaceuticals Corporation |
Selective neuropeptide y2 receptor agonists
|
|
WO2006037810A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
|
US7410949B2
(en)
|
2005-01-18 |
2008-08-12 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
|
|
US20080153779A1
(en)
|
2005-02-01 |
2008-06-26 |
Jun Liao |
Gastric Retention and Controlled Release Delivery System
|
|
EP2256130B1
(en)
|
2005-02-02 |
2013-09-25 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
CA2599723A1
(en)
|
2005-03-04 |
2006-09-14 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
|
GB0504857D0
(en)
|
2005-03-09 |
2005-04-13 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
JP2008533104A
(ja)
|
2005-03-18 |
2008-08-21 |
ノボ ノルディスク アクティーゼルスカブ |
Ｇｌｐ−１受容体の二量体ペプチドアゴニスト
|
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
EP1863521B1
(en)
|
2005-03-18 |
2014-05-07 |
Novo Nordisk A/S |
Extended glp-1 compounds
|
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
EP1863449A2
(en)
|
2005-03-28 |
2007-12-12 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
|
WO2007008778A2
(en)
|
2005-07-11 |
2007-01-18 |
Nastech Pharmaceutical Company Inc. |
Formulations for enhanced mucosal delivery of pyy
|
|
US8975227B2
(en)
|
2005-07-15 |
2015-03-10 |
Emisphere Technologies, Inc. |
Intraoral dosage forms of glucagon
|
|
BRPI0613984A2
(pt)
|
2005-07-18 |
2011-03-01 |
Novo Nordisk As |
peptìdios para uso no tratamento da obesidade, seu uso e composição farmacêutica compreendendo os mesmos
|
|
DK3524261T5
(da)
|
2005-08-19 |
2024-09-02 |
Amylin Pharmaceuticals Llc |
Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt
|
|
US20070049557A1
(en)
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
|
EP1934254A1
(en)
|
2005-09-21 |
2008-06-25 |
7TM Pharma A/S |
Y4 selective receptor agonists for therapeutic interventions
|
|
JP2009508886A
(ja)
|
2005-09-21 |
2009-03-05 |
７ティーエム ファーマ エイ／エス |
治療的介入のためのｙ２選択性レセプターアゴニスト
|
|
WO2007061434A2
(en)
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
|
CN101309674A
(zh)
|
2005-11-17 |
2008-11-19 |
诺瓦提斯公司 |
药物组合物
|
|
JP5000663B2
(ja)
|
2005-12-07 |
2012-08-15 |
エフ．ホフマン−ラ ロシュ アーゲー |
神経ペプチド２受容体アゴニスト
|
|
JP2009520693A
(ja)
|
2005-12-08 |
2009-05-28 |
エムディーアールエヌエー，インコーポレイテッド |
安定化されたエキセンディン製剤の粘膜送達
|
|
EP1963343A1
(en)
|
2005-12-14 |
2008-09-03 |
Novo Nordisk A/S |
Polypeptide protracting tags
|
|
US20070197445A1
(en)
|
2006-01-18 |
2007-08-23 |
University Of Cincinnati |
Compounds for control of appetite
|
|
JP5412273B2
(ja)
|
2006-03-21 |
2014-02-12 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
ペプチド−ぺプチダーゼ阻害剤及びその使用
|
|
CA2648594C
(en)
|
2006-04-07 |
2012-10-16 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
|
US8927015B2
(en)
|
2006-04-12 |
2015-01-06 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
|
EP2015770B1
(en)
|
2006-05-09 |
2012-09-26 |
Novo Nordisk A/S |
Insulin derivative
|
|
US20070292512A1
(en)
|
2006-06-09 |
2007-12-20 |
Merrion Research Ii Limited |
Solid Oral Dosage Form Containing an Enhancer
|
|
EP2040718B1
(en)
|
2006-06-28 |
2017-12-27 |
Emisphere Technologies, Inc. |
Gallium nitrate formulations
|
|
GB0613196D0
(en)
|
2006-07-03 |
2006-08-09 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
ES2296529B1
(es)
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
Composicion farmaceutica con promotores de absorcion.
|
|
JP5021033B2
(ja)
|
2006-09-07 |
2012-09-05 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｓｎａｃ（サルカプロザートナトリウム）の製造法
|
|
CL2007002634A1
(es)
|
2006-09-13 |
2008-05-16 |
Smithkline Beecham Corp |
Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion.
|
|
JP5864834B2
(ja)
|
2006-09-22 |
2016-02-17 |
ノボ・ノルデイスク・エー／エス |
プロテアーゼ耐性のインスリンアナログ
|
|
PE20080845A1
(es)
|
2006-09-22 |
2008-08-13 |
Novartis Ag |
Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
|
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
|
WO2008070543A1
(en)
|
2006-12-01 |
2008-06-12 |
Emisphere Technologies Inc. |
Improved acyclovir formulations
|
|
US20090099074A1
(en)
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
|
EP2106405A2
(en)
|
2007-01-18 |
2009-10-07 |
Novo Nordisk A/S |
Peptides for use in the treatment of obesity
|
|
US20100022446A1
(en)
|
2007-01-18 |
2010-01-28 |
Novo Nordisk A/S |
Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
|
|
KR101564114B1
(ko)
|
2007-03-02 |
2015-10-28 |
노파르티스 아게 |
칼시토닌의 경구 투여
|
|
GB0708226D0
(en)
|
2007-04-27 |
2007-06-06 |
7Tm Pharma As |
Y-receptor agonists
|
|
US8835381B2
(en)
|
2007-06-12 |
2014-09-16 |
Glaxosmithkline Llc |
Methods for detecting protein in plasma
|
|
EP2322620A3
(en)
|
2007-07-09 |
2011-08-31 |
Imperial Innovations Ltd. |
Analogs of human pancreatic polypeptide and their effects on feeding behaviour
|
|
WO2009032749A2
(en)
|
2007-08-29 |
2009-03-12 |
The Regents Of The University Of Californina |
Salicylanilide modified peptides for use as oral therapeutics
|
|
EP2190460B1
(en)
|
2007-09-05 |
2014-12-17 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
JP5476304B2
(ja)
|
2007-09-05 |
2014-04-23 |
ノボ・ノルデイスク・エー／エス |
グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
|
|
EP2190873B1
(en)
|
2007-09-05 |
2015-07-22 |
Novo Nordisk A/S |
Truncated glp-1 derivatives and their therapeutical use
|
|
RU2010114061A
(ru)
|
2007-09-11 |
2011-10-20 |
Мондобайотек Лабораториз Аг (Li) |
ПРИМЕНЕНИЕ ПЕПТИДА His-Ser-Leu-Gly-Lys-Trp-Leu-His-Pro-Asp-Lys-Phe ИНДИВИДУАЛЬНО ИЛИ В КОМБИНАЦИИ С ПЕПТИДОМ Gly-Arg-Gly-Asp-Asn-Pro-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
|
|
WO2009042922A2
(en)
|
2007-09-27 |
2009-04-02 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of making and using same
|
|
RU2453332C2
(ru)
|
2007-10-16 |
2012-06-20 |
Байокон Лимитид |
Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
|
|
CN101952241B
(zh)
|
2007-11-02 |
2014-06-11 |
艾米斯菲尔技术公司 |
治疗维生素b12缺乏的方法
|
|
US20090124639A1
(en)
|
2007-11-06 |
2009-05-14 |
Emisphere Technologies Inc. |
valacyclovir formulations
|
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
|
AU2009248041B2
(en)
|
2008-05-16 |
2013-10-03 |
Novo Nordisk A/S |
Long-acting Y2 and/or Y4 receptor agonists
|
|
US9186412B2
(en)
|
2008-08-18 |
2015-11-17 |
Entera Bio Ltd. |
Methods and compositions for oral administration of insulin
|
|
CN102149411A
(zh)
|
2008-09-12 |
2011-08-10 |
诺沃—诺迪斯克有限公司 |
酰化肽或蛋白的方法
|
|
US8299023B2
(en)
|
2008-09-17 |
2012-10-30 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists
|
|
GB0817067D0
(en)
|
2008-09-18 |
2008-10-22 |
7Tm Pharma As |
Intestinal treatment
|
|
JP5744741B2
(ja)
|
2008-10-15 |
2015-07-08 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
植物病原菌類の防除のためのジチイン−テトラカルボキシミドの使用
|
|
KR20110097807A
(ko)
|
2008-11-05 |
2011-08-31 |
에프. 호프만-라 로슈 아게 |
뉴로펩티드-2-수용체(ｙ-2ｒ) 작용제 및 이의 용도
|
|
CN101463081B
(zh)
|
2009-01-12 |
2012-07-04 |
华东师范大学 |
一种glp-1衍生物
|
|
NZ594044A
(en)
|
2009-02-13 |
2014-08-29 |
Boehringer Ingelheim Int |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
|
KR101413051B1
(ko)
|
2009-02-20 |
2014-07-31 |
입센 파마 에스.에이.에스 |
뉴로펩타이드 ｙ 수용체 결합성 화합물을 포함하는 세포독성 접합체
|
|
AR077956A1
(es)
|
2009-09-14 |
2011-10-05 |
Bayer Cropscience Ag |
Combinaciones de compuestos activos
|
|
EP2477643A1
(en)
|
2009-09-18 |
2012-07-25 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
|
IN2012DN03042A
(pl)
|
2009-10-13 |
2015-07-31 |
Hoffmann La Roche |
|
|
EP2498800A1
(en)
|
2009-11-13 |
2012-09-19 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
|
CN104311657B
(zh)
*
|
2009-12-16 |
2020-12-08 |
诺沃—诺迪斯克有限公司 |
双酰化glp-1衍生物
|
|
CA2784120A1
(en)
|
2009-12-16 |
2011-07-14 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
|
WO2011109787A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Methods of administering insulinotropic peptides
|
|
GB2478849A
(en)
|
2010-03-16 |
2011-09-21 |
Chiasma Inc |
Improved pharmecutical compositions and methods of delivery
|
|
EP2560675A1
(en)
|
2010-04-20 |
2013-02-27 |
Novo Nordisk A/S |
Long-acting gastrin derivatives
|
|
BR112012027893A2
(pt)
*
|
2010-04-30 |
2019-09-24 |
Sanwa Kagaku Kenkyusho Ltd |
peptídeo para aumento da bioestabilidade de substância bioativa e substância biotiva que possui bioestabilidade aumentada.
|
|
CA2797310C
(en)
|
2010-05-05 |
2020-03-31 |
Boehringer Ingelheim International Gmbh |
Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
|
|
DE202010015867U1
(de)
|
2010-11-25 |
2011-05-05 |
Buchhalter, Thomas |
Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
|
|
HUE036066T2
(hu)
|
2010-12-16 |
2018-06-28 |
Novo Nordisk As |
GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
|
|
GB201101459D0
(en)
|
2011-01-27 |
2011-03-16 |
Imp Innovations Ltd |
Novel compounds and thier effects on fedding behaviour
|
|
WO2012140117A1
(en)
|
2011-04-12 |
2012-10-18 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
EP2729481B1
(en)
|
2011-07-08 |
2018-10-17 |
Amylin Pharmaceuticals, LLC |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
|
HUE042757T2
(hu)
|
2012-03-22 |
2019-07-29 |
Novo Nordisk As |
Szállító szert tartalmazó készítmények és elõállításuk
|
|
ES2965469T3
(es)
|
2012-03-22 |
2024-04-15 |
Novo Nordisk As |
Composiciones que comprenden un agente de suministro y preparación de estas
|
|
EP2827885B1
(en)
|
2012-03-22 |
2018-08-15 |
Novo Nordisk A/S |
Compositions of glp-1 peptides and preparation thereof
|
|
EP2855517A1
(en)
|
2012-05-29 |
2015-04-08 |
Novo Nordisk A/S |
Pancreatic polypeptide compounds and use
|
|
EP2863895B1
(en)
|
2012-06-20 |
2021-04-14 |
Novo Nordisk A/S |
Tablet formulation comprising a peptide and a delivery agent
|
|
CA2877056A1
(en)
|
2012-07-01 |
2014-01-09 |
Novo Nordisk A/S |
Use of long-acting glp-1 peptides
|
|
PL2991671T3
(pl)
|
2013-05-02 |
2019-01-31 |
Novo Nordisk As |
Doustne dawkowanie związków glp-1
|
|
US20160108098A1
(en)
|
2013-05-02 |
2016-04-21 |
Glaxosmithkline Intellectual Property Development Limited |
Therapeutic peptides
|
|
US9085637B2
(en)
|
2013-11-15 |
2015-07-21 |
Novo Nordisk A/S |
Selective PYY compounds and uses thereof
|
|
EP3068795B1
(en)
|
2013-11-15 |
2019-03-06 |
Novo Nordisk A/S |
Hpyy(1-36) having a beta-homoarginine substitution at position 35
|
|
CA2975578A1
(en)
|
2015-02-09 |
2016-08-18 |
Entera Bio Ltd. |
Treatment of hypoparathyroidism
|
|
BR112017025108A2
(pt)
|
2015-06-12 |
2018-07-31 |
Novo Nordisk As |
compostos seletivos de pyy e usos dos mesmos
|
|
AU2016335287A1
(en)
|
2015-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
|
JP6898518B2
(ja)
|
2018-02-02 |
2021-07-07 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
|